Metformin combats obesity by targeting FTO in an m6A-YTHDF2-dependent manner
Xing Liao, Jiaqi Liu, Yushi Chen, Youhua Liu, Wei Chen, Botao Zeng, Yuxi Liu, Yaojun Luo, Chaoqun Huang, Guanqun Guo, Yizhen Wang, Xinxia Wang
Journal:JOURNAL OF DRUG TARGETING
IF:5.02
DOI:10.1080/1061186X.2022.2071906
PMID:35481401
Published:2022-05-09
research field:心血管生物学遗传学与基因组学生物化学
Abstract
Obesity has become a health threat and hard enough to deal with. Evidences show that metformin could inhibit adipogenesis and combat obesity, while its mechanisms remain to be elucidated more comprehensively. In this study, we found that administration of metformin could combat obesity of mice induced by high-fat diet (HFD), indicated by strikingly decreased body weight and weight of inguinal white adipose tissue (iWAT) and epidydimal white adipose tissue (eWAT) compared with the control group. Mechanically, we revealed that metformin could inhibit protein expression of FTO, leading to increased m6A methylation levels of cyclin D1 (Ccnd1) and cyclin dependent kinase 2 (Cdk2), two crucial regulators in cell cycle. Ccnd1 and Cdk2 with increased m6A levels were recognised by YTH m6A RNA binding protein 2 (YTHDF2), causing an YTHDF2-dependent decay and decreased protein expressions. In consequence, mitotic clonal expansion (MCE) process was blocked and adipogenesis was inhibited.
本文使用的Yeasen产品


